BP control over the long term, omecamtiv mecarbil, incentives and Goodhart’s law, and open science are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Long-Term BP Control
- Final SPRINT Data Confirm Lower BP Is Better https://www.medscape.com/viewarticle/951572
- Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://jamanetwork.com/journals/jamacardiology/fullarticle/2797064
- Let's Not SPRINT to Judgment About New Blood Pressure Goals https://www.acpjournals.org/doi/full/10.7326/M15-3123
- Should We SPRINT Toward New Blood Pressure Goals or Let the Dust Settle? https://doi.org/10.1016/j.amjmed.2016.04.022
II. Omecamtiv Mecarbil
- FDA Panel Votes No on Omecamtiv Mecarbil for Heart Failure https://www.medscape.com/viewarticle/985593
- Omecamtiv Mecarbil Fails to Improve Exercise Capacity in HFrEF https://www.medscape.com/viewarticle/978355
- Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2025797
- Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction https://jamanetwork.com/journals/jama/fullarticle/2794362
- Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial https://doi.org/10.1093/eurheartj/ehac293
III. Measuring Quality of Care
- MIPS Quality Scores Don't Reflect Quality of Care: Study https://www.medscape.com/viewarticle/985396
- Association Between Individual Primary Care Physician Merit-based Incentive Payment System Score and Measures of Process and Patient Outcomes https://jamanetwork.com/journals/jama/article-abstract/2799153
- Pay for Performance When Slogans Overtake Science in Health Policy https://jamanetwork.com/journals/jama/fullarticle/2799177
- Goodhart's law https://en.wikipedia.org/wiki/Goodhart%27s_law
IV. Open Science
- Radial Artery Outlasts SVG as Second CABG Conduit, Cuts 5-Year Clinical Risk https://www.medscape.com/viewarticle/896122
- Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results https://doi.org/10.1177/2515245917747646
- Radial artery versus saphenous vein versus right internal thoracic artery for coronary artery bypass grafting https://academic.oup.com/ejcts/article/62/1/ezac345/6604735?login=false
- Do all roads lead to Rome? Critical reassessment of the individual patient meta-analysis on bypass grafts by Gaudino et al. https://doi.org/10.1093/ejcts/ezac564
- Editorial: Radial artery versus saphenous vein versus right internal thoracic artery for coronary artery bypass grafting: Different conduits or different trials? https://doi.org/10.1093/ejcts/ezac562
Features
- Mandrola’s Top 10 Cardiology Stories of 2022 https://www.medscape.com/viewarticle/985607
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net